Examples of using Carcinogenicity study in English and their translations into German
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
A carcinogenicity study in rats is ongoing.
The relevance of the findings from the rat carcinogenicity study for humans is not known.
The carcinogenicity study in the rat did not reveal any effect which may be relevant for humans.
Nitisinone did not show carcinogenic potential in a 26-week carcinogenicity study in transgenic mice TgrasH2.
In a 2-year rat carcinogenicity study, one case of hibernoma was found.
People also translate
In rats decreased cellularity of the bone marrow andthymic atrophy were observed only in the carcinogenicity study.
In rats a 2-year carcinogenicity study demonstrates at a dose of.
A carcinogenicity study with buprenorphine/naloxone was conducted in rats at doses of 7, 30 and.
In the absence of similar findings in females,no findings in the genotoxicity battery or in the carcinogenicity study with Tg.rasH2 mice, and no pre-neoplastic pancreatic findings in the rodents or monkeys, this observation in male rats is not considered related to treatment and its relevance to humans is unknown.
In a rat carcinogenicity study with oxybate no compound-related tumours were identified.
A two-year mouse carcinogenicity study produced no evidence of carcinogenicity by capecitabine.
A carcinogenicity study was conducted testing the skin of mice during 21 months.
In the rat carcinogenicity study, benign tumours were found in the small bowel and the extrahepatic bile ducts.
In a rat carcinogenicity study, the incidence of endocardial tumours was elevated in females receiving the top dose.
A two-year mouse carcinogenicity study by dermal administration on three days a week did not induce tumours at the application site.
In a carcinogenicity study, male rats developed Leydig cell hyperplasia and adenomas, explained by the prolactin-inhibiting effect of pramipexole.
In a 2-year carcinogenicity study in female mice, ospemifene caused treatment related increases in neoplastic findings in the adrenal gland and ovary.
In a rat carcinogenicity study increases in benign tumours of the mammary gland(fibroadenoma), uterus(polyp) and thyroid(C-cell adenoma) were noted in females.
In a 24-month intramuscular carcinogenicity study in rats, no increased incidence of injection site tumours was seen in either the vehicle or active groups.
A carcinogenicity study(daily subcutaneous injections of fentanyl hydrochloride for two years in Sprague Dawley rats) did not induce any findings indicative of oncogenic potential.
In a 2-year carcinogenicity study in rats, an increased incidence of benign, ovarian granulosa-cell tumours was observed in female rats at dietary concentrations of 0.03% and 0.1.
In a two-year rat carcinogenicity study, non-neoplastic and neoplastic findings were observed and related or attributed to an exaggerated pharmacological effect.
In the 2-year rat carcinogenicity study administration of imatinib at 15, 30 and 60 mg/kg/day resulted in a statistically significant reduction in the longevity of males at 60 mg/kg/day and females at.
In a carcinogenicity study of rats exposed to 2,6-xylidine in utero, postnatally and throughout their lifetime, tumours in the nasal cavity, subcutaneous tumours and liver tumours were observed.
In a carcinogenicity study in mice an increased incidence of malignant lymphoma occurred in males of the highest dose group, considered to be due to the immunosuppressive activity of leflunomide.
In a mouse carcinogenicity study at dosages corresponding to 0.1 and 0.7 times the clinical exposure(based on AUC), there were no significant differences from controls in the incidence of tumors.
In the 2-year rat carcinogenicity study administration of imatinib at 15, 30 and 60 mg/ kg/ day resulted in a statistically significant reduction in the longevity of males at 60 mg/ kg/ day and females at≥ 30 mg/ kg/ day.
In a 21-month carcinogenicity study in mice, there was an increased incidence of testicular interstitial cell tumours and prostatic adenomas and adenocarcinomas in males given 41 or 210 mg/ kg, and prostatic leiomyoblastoma in males given 210 mg/ kg.
In a 2-year carcinogenicity study in rats, at≥ 7 times the human clinical exposure following 1.5 mg dulaglutide per week, dulaglutide caused statistically significant, dose-related increases in the incidence of thyroid C-cell tumours adenomas and carcinomas combined.
Thyroid gland tumours found in a rat carcinogenicity study and hepatocellular neoplasms found in a mouse carcinogenicity study are considered to be species-specific, non-genotoxic responses associated with long-term treatment with high doses of hepatic enzyme inducers.